Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Dainippon Sumitomo Pharma Co. Ltd. Stories

2014-03-10 00:21:49

First subject enrolled in pivotal clinical trial MOUNTAIN VIEW, Calif., March 10, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled, "A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome" to be conducted in conjunction with Dainippon Sumitomo Pharma Co, Ltd. The trial is an open-label study lasting six months. To be eligible for the trial, children must have clinical and radiographic evidence of Leigh...

2014-02-04 23:27:41

MitoAction and UMDF have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd. of Japan. (PRWEB) February 04, 2014 The nation’s leading mitochondrial disease patient advocacy organizations have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd....

2013-11-14 16:27:40

CAMBRIDGE, Mass., Nov. 14, 2013 /PRNewswire/ -- Boston Biomedical, Inc. and Boston Biomedical Pharma Inc., collectively "Boston Biomedical", announced that it has appointed Patricia S. Andrews as Executive Vice President and Chief Commercial Officer as it begins strategic planning and preparations for the commercialization of its cancer stem cell inhibitors with its lead asset, BBI608, currently in a global Phase 3 clinical trial for metastatic colorectal cancer. Boston Biomedical is...

2013-10-14 23:20:31

Reportbuyer.com just published a new market research report: Global Pulmonary Drug Delivery Systems Market 2012-2016. London (PRWEB) October 14, 2013 TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been...

2013-10-09 04:21:12

OSAKA, Japan, Oct. 9, 2013 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. (DSP) announced on October 9 that it has decided to establish an anti-cancer drugs sales company in the United States as a wholly-owned subsidiary of DSP's 100% owned U.S. holding company. 1. Objectives of establishing the sales company DSP is conducting a Phase III global clinical study of the anti-cancer drug BBI608 that was created by its U.S. subsidiary Boston Biomedical, Inc. ("BBI"). In this...

2013-07-12 20:20:26

CAMBRIDGE, Mass., July 12, 2013 /PRNewswire/ -- Boston Biomedical, Inc. this week celebrated the relocation of its headquarters to Cambridge, Massachusetts with a grand opening ceremony. Academic, business and government leaders, as well as executives from Dainippon Sumitomo Pharma Co., Ltd. (DSP), the parent company of BBI, joined the celebration. "We are pleased to celebrate the opening of our new facility, which will greatly expand the efforts of the Boston Biomedical team in our...

2013-03-28 08:29:16

MOUNTAIN VIEW, Calif., March 28, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization agreement with Dainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of EPI-743 and EPI-589 in Japan. Under the terms of the agreement, DSP will gain development and commercialization rights in Japan in exchange for Edison receiving $35 million in upfront and $15 million in R&D support. In addition, Edison will...

2012-10-25 07:32:00

OSAKA, Japan, October 25, 2012 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization Application (MAA) for an atypical antipsychotic medication lurasidone hydrochloride for the treatment of schizophrenia. The MAA was filed by Takeda...

2011-04-07 04:00:00

OSAKA, Japan and NORWOOD, Mass., April 7, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Boston Biomedical, Inc. ("BBI"), today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada. BBI608 is an orally administered, first-in-class, small molecule anti-cancer drug that targets highly malignant cancer stem cells as well as other...

2011-03-30 05:03:00

OSAKA, Japan and NEW YORK, March 30, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid (OCA, also known as INT-747). DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, with an initial focus on primary biliary cirrhosis...